Division of Gastroenterology, Baylor Scott & White Health, Texas A&M Health Science Center, Temple, Texas.
Department of Anatomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Clin Gastroenterol Hepatol. 2018 Jun;16(6):900-907.e1. doi: 10.1016/j.cgh.2017.12.034. Epub 2017 Dec 24.
BACKGROUND & AIMS: Epithelioid granulomas are characteristics of a subset of patients with Crohn's disease (CD), but their significance, with regard to disease progression and severity, is unclear. We investigated the relationship between granulomas and CD severity over a 6-year time period in a large cohort of patients.
We performed a retrospective study of patients with CD seen at the Inflammatory Bowel Disease Center at the University of Pittsburgh; data were collected from 2009 through 2014 and patients were assigned to groups with and without histologic evidence of granuloma. Demographic, clinical (including disease activity, quality of life, medication use, and healthcare utilization), and laboratory data were used in association and survival analyses. Differences between groups were evaluated using the Mann-Whitney U-test for continuous variables.
Of 1466 patients with CD, granulomas were identified in 187 (12.8%). In the subset of patients who underwent surgery, 21.0% had granulomas. The presence of granuloma was associated with increased serum levels of c-reactive protein (odds ratio [OR], 2.9; 95% CI, 2.078-4.208; P < .0001), younger mean age at diagnosis (23.6 ± 11.3 years in patients with granulomas vs 27.9 ± 13.3 years in patients without; P = .0005), higher rates of stricturing or penetrating disease phenotype, higher rates of steroid and narcotic use, and higher healthcare utilization. Among patients that underwent surgery, the presence of granulomas was associated with need for repeat surgery during the 6-year observation period (OR, 2.5; 95% CI, 1.54-4.02; P = .0002). Infliximab use was associated with detection of granuloma in a significantly lower proportion of surgical specimens compared to patients who had not been treated with a biologic agent (OR, 0.22; 95 CI, 0.05-0.97; P = .03).
Epithelioid granulomas develop in less than 13% of patients with CD, and are associated with a more aggressive disease phenotype. Patients who have undergone surgery for CD and have granulomas are at increased risk for repeat surgery within 6 years.
类上皮肉芽肿是克罗恩病(CD)患者亚群的特征,但它们与疾病进展和严重程度的关系尚不清楚。我们在一个大型 CD 患者队列中研究了 6 年内肉芽肿与 CD 严重程度的关系。
我们对匹兹堡大学炎症性肠病中心就诊的 CD 患者进行了回顾性研究;数据收集自 2009 年至 2014 年,患者被分为有组织学证据的肉芽肿组和无组织学证据的肉芽肿组。关联和生存分析中使用了人口统计学、临床(包括疾病活动度、生活质量、药物使用和医疗保健利用)和实验室数据。使用 Mann-Whitney U 检验评估组间差异。
在 1466 例 CD 患者中,187 例(12.8%)发现有肉芽肿。在接受手术的患者亚组中,21.0%有肉芽肿。肉芽肿的存在与 C 反应蛋白血清水平升高相关(比值比[OR],2.9;95%可信区间[CI],2.078-4.208;P<.0001)、平均年龄更小(有肉芽肿的患者为 23.6±11.3 岁,无肉芽肿的患者为 27.9±13.3 岁;P=0.0005)、狭窄或穿透性疾病表型发生率更高、类固醇和麻醉药物使用率更高、以及医疗保健利用率更高。在接受手术的患者中,肉芽肿的存在与 6 年观察期内需要再次手术相关(OR,2.5;95%CI,1.54-4.02;P=.0002)。与未接受生物制剂治疗的患者相比,英夫利昔单抗治疗的患者手术标本中肉芽肿的检出率显著降低(OR,0.22;95%CI,0.05-0.97;P=0.03)。
上皮样肉芽肿在不到 13%的 CD 患者中发展,与侵袭性更强的疾病表型相关。接受过 CD 手术且有肉芽肿的患者在 6 年内再次手术的风险增加。